US-China Economic and Trade Agreement Phase 1-Pharmacutical related IP issues
Registration and breakfast
Richard Glanton, Chairman of Board of directors of UCIPF
Overview of IP provisions of the recent Economic and Trade Agreement between U.S. and China phase 1
Mark Cohen, Lecturer in Law, Distinguished Senior Fellow, and Director at the University of California at Berkeley
Advisory Board, UCIPF
US-China Economic and Trade agreement phase 1 signed, what does it mean to US companies and IP lawyers
Randall Rader, Former Chief Judge of US Federal Circuit of Patent Appeal court
Board of Directors, Trustee, UCIPF
Supplemental Data filing in China and Patent Term Extension
- Current practice for post filing data in China
Luke Zuo, Senior Partner, NTD Patent & Trademark Agency Limited
- Current challenges for US Pharmaceutical companies for posting filing data issues in China
Craig R. Tucker, Senior Patent Counsel, Eli Lilly
- What we expect that China implement the IP provisions of the Economic and Trade Agreement in the future for Post filing data
US Lawyer; Chinese Lawyer
- Patent Term Extension
Tom Hoxie, Managing Partner, Hoxie & Associates LLC.
- Is China implementing a new linkage regime as a result of this Phase 1 Agreement? How is it different from the prior voluntary system?
Johnathan Miao, Senior Partner, NTD Patent & Trademark Agency Limited
- Has China implemented an orange book type regime to identify approved pharma products that have patent protection? Is it working in deterring regulatory approval of infringing products?
Benjamin Hsing, Partner, McguireWoods LLP
- The agreement doesn’t spell out a regime of “artificial infringement” for linkage. Can China implement a linkage regime without “artificial infringement.”?
Closing remarks-Demi Wang